Evidence map›Paper›PMID 40713414›Full record

ReviewInternational psychogeriatrics2026

Brief operationalized psychosocial interventions for agitation and psychosis: Use in clinical trials and clinical care.

Clive Ballard, Kathryn Mills, Maria Soto, Jeffery Cummings, Jacobo Mintzer, George Grossberg, Manabu Ikeda, Sanjeev Pathak, Corinne Fischer, Joanne McDermid

Abstract readReview
In one paragraph

Review in International psychogeriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clive BallardDepartment of Health and Community Sciences, Faculty of Life Sciences, University of Exeter, UK. Electronic address: c.ballard@exeter.ac.uk.
Kathryn MillsDepartment of Health and Community Sciences, Faculty of Life Sciences, University of Exeter, UK.
Maria SotoUniversity of Toulouse III, F-31073 Toulouse, France; Department of Geriatric Medicine, Institute of Ageing, Toulouse University Hospital, Toulouse, France.
Jeffery CummingsDepartment of Health and Community Sciences, Faculty of Life Sciences, University of Exeter, UK; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, USA.
Jacobo MintzerDepartment of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.
George GrossbergDepartment of Psychiatry & Behavioral Neuroscience, Division of Geriatric Psychiatry, St Louis University School of Medicine, MO, USA.
Manabu IkedaDepartment of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan.
Sanjeev PathakACADIA Pharmaceuticals Inc., Princeton, NJ, USA.
Corinne FischerKeenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Joanne McDermidDepartment of Health and Community Sciences, Faculty of Life Sciences, University of Exeter, UK.

Funding

Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI JESSICA KIRKLAND CALDWELL · 2015 to 2026
$22.8M
Alzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9M
NIA NIH HHS R35 AG071476NIGMS NIH HHS P20 GM109025
6 · The paper itself

Abstract

backgroundNeuropsychiatric symptoms such as agitation and/or psychosis impact most individuals with dementia during their illness, leading to reduced quality of life, distress, more rapid clinical decline, and an increased risk of institutionalization. Widely used pharmacological approaches have modest benefits and are associated with significant adverse events.

methodsA narrative review was conducted to examine the evidence for the benefits of non-pharmacological treatments for agitation and psychosis in people with dementia, with a focus on operationalized approaches that could readily be introduced into clinical practice. In the absence of substantial evidence pertaining to non-pharmacological treatments of psychosis, the review was supplemented with a secondary analysis of an existing WHELD/BPST dataset.

resultsThere is substantial evidence that simple non-pharmacological treatment approaches, such as personalized activities with social interaction, are effective in the treatment of agitation or enabling the reduction of psychotropic medication without worsening of agitation. Examples are presented of several operationalized approaches suitable for clinical implementation. In contrast, the treatment response of psychotic symptoms in people with dementia to non-pharmacological approaches is less clear cut. There is emerging evidence that although currently used non-pharmacological approaches do not directly improve psychosis in people with dementia, they do improve quality of life and concurrent neuropsychiatric symptoms such as apathy and agitation. DISCUSSION: Although best practice guidelines universally recommend non-pharmacological interventions as the first-line treatment for neuropsychiatric symptoms, implementation has been limited. Several tools, such as Brief Psychosocial Therapy, are described which may help bridge this gap into clinical practice.

Indexed as

DementiaPsychomotor AgitationPsychosocial InterventionPsychotic DisordersClinical Trials as TopicHumansQuality of LifeAgitationDementiaNon-pharmacological treatmentPsychosis

Identifiers

PMID40713414
PMCPMC13557243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.